An expanded set of data from the PLIANT study was recently presented at the MASCC congress in Copenhagen. Besides confirming the results that were already known, the presentation contained certain new data, including results from three different methods for measuring symptoms of nerve damage which all showed a positive trend for PledOx compared with a placebo. In addition, data from the study indicate that the symptoms of nerve damage occurring despite pre-treatment with PledOx (5 µmol/kg), occur later in treatment and disappear faster. PledOx demonstrated a good safety profile. No patients appear to have had to discontinue the PledOx treatment due to an accumulation of manganese in the brain. We are raising our expectations that PledOx will reach the market, and this is reflected in an increased fair value of SEK 58 (54). Note: This is a translation of the original report, written in Swedish, released the 9th of July